Phenotypes associated with this allele

• Allele Symbol: Tg(Gfap-cre)2Brn
• Allele Name: transgene insertion 2, Anton Berns
• Allele ID: MGI:2663939
• Summary: 10 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor^+ Rb1^tm2Brn/Rb1^tm2Brn Tg(Gfap-cre)2Brn/0	either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N)	MGI:5437516
cn2	Gt(ROSA)26Sor^tm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor^+ Rb1^tm2Brn/Rb1^tm2Brn Trp53^tm1Brn/Trp53^tm1Brn Tg(Gfap-cre)2Brn/0	either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N)	MGI:5437517
cn3	Gt(ROSA)26Sor^tm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor^+ Tg(Gfap-cre)2Brn/0	either: (involves: 129P2/OlaHsd * FVB/N) or (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	MGI:5437515
cn4	Rb1^tm2Brn/Rb1^tm2Brn Trp53^tm1Brn/Trp53^tm1Brn Tg(Gfap-cre)2Brn/0	involves: 129 * 129P2/OlaHsd * FVB/N	MGI:5437518
cn5	Rb1^tm2Brn/Rb1^tm2Brn Trp53^tm1Brd/Trp53^tm1Brd Tg(Gfap-cre)2Brn/0	involves: 129 * 129S7/SvEvBrd * FVB/N	MGI:3804216
cn6	Tnfrsf11a^tm1.1Pngr/Tnfrsf11a^tm1.2Pngr Tg(Gfap-cre)2Brn/0	involves: 129 * C57BL/6 * C57BL/6NTac * FVB/N	MGI:4415817
cn7	Rb1^tm2Brn/Rb1^tm2Brn Tg(Gfap-cre)2Brn/0	involves: 129 * FVB/N	MGI:3804218
cn8	Rb1^tm2Brn/Rb1^tm2Brn Trp53^tm1Brn/Trp53^tm1Brn Tg(Gfap-cre)2Brn/0	involves: 129P2/OlaHsd * FVB/N	MGI:3804217
cn9	Trp53^tm1Brn/Trp53^tm1Brn Tg(Gfap-cre)2Brn/0	involves: 129P2/OlaHsd * FVB/N	MGI:3804219
cn10	Slc6a9^tm1Veul/Slc6a9^tm1Veul Tg(Gfap-cre)2Brn/?	involves: 129P2/OlaHsd * FVB/N	MGI:4818489

Genotype
MGI:5437516

cn1

• Allelic Composition: Gt(ROSA)26Sor^{tm1(CAG-Bmi1,-EGFP)Nki}/Gt(ROSA)26Sor⁺; Rb1^tm2Brn/Rb1^tm2Brn; Tg(Gfap-cre)2Brn/0
• Genetic Background: either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N)

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:187257 )

neoplasm

neoplasm ( J:187257 )

N • mice do not develop medulloblastoma

increased pituitary gland tumor incidence ( J:187257 )

endocrine/exocrine glands

increased pituitary gland tumor incidence ( J:187257 )

nervous system

increased pituitary gland tumor incidence ( J:187257 )

Genotype
MGI:5437517

cn2

• Allelic Composition: Gt(ROSA)26Sor^{tm1(CAG-Bmi1,-EGFP)Nki}/Gt(ROSA)26Sor⁺; Rb1^tm2Brn/Rb1^tm2Brn; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Gfap-cre)2Brn/0
• Genetic Background: either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N)

neoplasm

increased pituitary gland tumor incidence ( J:187257 )

increased medulloblastoma incidence ( J:187257 )

• as in Rb1^tm2Brn/Rb1^tm2Brn Trp53^tm1Brn/Trp53^tm1Brn Tg(Gfap-cre)2Brn mice

increased carcinoma incidence ( J:187257 )

• large cell carcinoma

endocrine/exocrine glands

increased pituitary gland tumor incidence ( J:187257 )

nervous system

increased pituitary gland tumor incidence ( J:187257 )

increased medulloblastoma incidence ( J:187257 )

• as in Rb1^tm2Brn/Rb1^tm2Brn Trp53^tm1Brn/Trp53^tm1Brn Tg(Gfap-cre)2Brn mice

Genotype
MGI:5437515

cn3

• Allelic Composition: Gt(ROSA)26Sor^{tm1(CAG-Bmi1,-EGFP)Nki}/Gt(ROSA)26Sor⁺; Tg(Gfap-cre)2Brn/0
• Genetic Background: either: (involves: 129P2/OlaHsd * FVB/N) or (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)

Pituitary tumor in Gt(ROSA)26Sor^{tm1(CAG-Bmi1,-EGFP)Nki}/Gt(ROSA)26Sor⁺ Tg(Gfap-cre)2Brn/0 mice

mortality/aging

premature death ( J:187257 )

neoplasm

increased tumor incidence ( J:187257 )

• pituitary tumors, mammary gland tumors and primitive neuroectodermal tumors

increased pituitary gland tumor incidence ( J:187257 )

• 8 of 16 solid tumors with a latency of a year

• intermediate and anterior lobe

• positive for adrenocorticotropic hormone

increased mammary gland tumor incidence ( J:187257 )

nervous system

increased pituitary gland tumor incidence ( J:187257 )

• 8 of 16 solid tumors with a latency of a year

• intermediate and anterior lobe

• positive for adrenocorticotropic hormone

endocrine/exocrine glands

increased pituitary gland tumor incidence ( J:187257 )

• 8 of 16 solid tumors with a latency of a year

• intermediate and anterior lobe

• positive for adrenocorticotropic hormone

increased mammary gland tumor incidence ( J:187257 )

integument

increased mammary gland tumor incidence ( J:187257 )

Genotype
MGI:5437518

cn4

• Allelic Composition: Rb1^tm2Brn/Rb1^tm2Brn; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Gfap-cre)2Brn/0
• Genetic Background: involves: 129 * 129P2/OlaHsd * FVB/N

neoplasm

increased pituitary gland tumor incidence ( J:187257 )

increased medulloblastoma incidence ( J:187257 )

increased carcinoma incidence ( J:187257 )

• large cell carcinoma

increased papilloma incidence ( J:187257 )

• choroid plexus papilloma

nervous system

increased pituitary gland tumor incidence ( J:187257 )

increased medulloblastoma incidence ( J:187257 )

endocrine/exocrine glands

increased pituitary gland tumor incidence ( J:187257 )

Genotype
MGI:3804216

cn5

• Allelic Composition: Rb1^tm2Brn/Rb1^tm2Brn; Trp53^tm1Brd/Trp53^tm1Brd; Tg(Gfap-cre)2Brn/0
• Genetic Background: involves: 129 * 129S7/SvEvBrd * FVB/N

neoplasm

increased medulloblastoma incidence ( J:61961 )

• mutants develop highly aggressive embryonal tumors of the cerebellum with typical features of medulloblastoma

• tumors are identified as early as 7 weeks of age on the outer surface of the molecular layer, corresponding to the location of the cerebellar external granular layer cells during development

behavior/neurological

tremors ( J:61961 )

ataxia ( J:61961 )

impaired balance ( J:61961 )

• loss of balance

• mutants hold their heads to one side

abnormal gait ( J:61961 )

• gait is disturbed with ataxia

circling ( J:61961 )

nervous system

increased medulloblastoma incidence ( J:61961 )

• mutants develop highly aggressive embryonal tumors of the cerebellum with typical features of medulloblastoma

• tumors are identified as early as 7 weeks of age on the outer surface of the molecular layer, corresponding to the location of the cerebellar external granular layer cells during development

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
medulloblastoma		DOID:0050902	OMIM:155255	J:61961

Genotype
MGI:4415817

cn6

• Allelic Composition: Tnfrsf11a^tm1.1Pngr/Tnfrsf11a^tm1.2Pngr; Tg(Gfap-cre)2Brn/0
• Genetic Background: involves: 129 * C57BL/6 * C57BL/6NTac * FVB/N

homeostasis/metabolism

abnormal body temperature homeostasis ( J:155398 )

• ovariectomized mice fail to exhibit a change in body temperature unlike similarly treated wild-type mice

abnormal circadian temperature homeostasis ( J:155398 )

• in female mice during the light phase

impaired febrile response ( J:155398 )

• mice injected with RANKL (Tnfsf11) or LPS fail to develop severe hyperthermia unlike similarly treated wild-type mice

decreased prostaglandin level ( J:155398 )

• mice injected with RANKL (Tnfsf11) fail to exhibit an increase in prostagladin levels unlike similarly treated wild-type mice

abnormal response/metabolism to endogenous compounds ( J:155398 )

• mice injected with RANKL (Tnfsf11) fail to develop severe hyperthermia and do not exhibit a change in diurnal activity unlike similarly treated wild-type mice

• mice injected with Il1b or TNF exhibit an impaired fever response and alterations in circadian activity compared with similarly treated wild-type mice

• mice injected with RANKL (Tnfsf11) fail to exhibit an increase in prostagladin levels unlike similarly treated wild-type mice

immune system

decreased susceptibility to endotoxin shock ( J:155398 )

• mice injected with LPS fail to develop severe hyperthermia and do not exhibit a change in diurnal activity unlike similarly treated wild-type mice

Genotype
MGI:3804218

cn7

• Allelic Composition: Rb1^tm2Brn/Rb1^tm2Brn; Tg(Gfap-cre)2Brn/0
• Genetic Background: involves: 129 * FVB/N

mortality/aging

premature death ( J:187257 )

neoplasm

neoplasm ( J:61961 )

N • mutants do not develop medulloblastomas

increased pituitary gland tumor incidence ( J:187257 )

increased carcinoma incidence ( J:187257 )

• large cell carcinoma

endocrine/exocrine glands

increased pituitary gland tumor incidence ( J:187257 )

nervous system

increased pituitary gland tumor incidence ( J:187257 )

Genotype
MGI:3804217

cn8

• Allelic Composition: Rb1^tm2Brn/Rb1^tm2Brn; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Gfap-cre)2Brn/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

neoplasm

increased medulloblastoma incidence ( J:61961 )

• mutants develop medulloblastomas

nervous system

increased medulloblastoma incidence ( J:61961 )

• mutants develop medulloblastomas

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
medulloblastoma		DOID:0050902	OMIM:155255	J:61961

Genotype
MGI:3804219

cn9

• Allelic Composition: Trp53^tm1Brn/Trp53^tm1Brn; Tg(Gfap-cre)2Brn/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

normal phenotype

no abnormal phenotype detected ( J:61961 )

• mutants are healthy and fertile and do not develop medulloblastomas and glial malignancies

Genotype
MGI:4818489

cn10

• Allelic Composition: Slc6a9^tm1Veul/Slc6a9^tm1Veul; Tg(Gfap-cre)2Brn/?
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

mortality/aging

postnatal lethality, incomplete penetrance ( J:161993 )

• hypotonic phenotype leads to premature death

• frequency of deaths peaks at around 3 days of age

• 20% of mice have a normal life span

muscle

hypotonia ( J:161993 )

• 80% of homozygotes show a strong hypotonic phenotype

• onset from day 1 through 10 days of age

• 20% of mice develop no phenotype